Cholera – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cholera is an acute diarrheal illness caused by infection with the bacterium Vibrio cholera, specifically the O1 and O139 serogroups. Upon ingestion, V. cholera killed by gastric acid, but surviving organisms colonize the small intestine and produce cholera toxin. Transmission occurs through contaminated food and water; risk factors include drinking untreated water and consuming certain foods, such as shellfish. Other risk factors include blood group O, hypochlorhydria, and partial gastrectomy. The clinical presentation of cholera is characterized by massive watery diarrhea, up to 1 liter per hour, which can lead to hypotensive shock and death within hours ("Cholera gravis"). Treatment primarily involves rehydration using oral rehydration solution (ORS), which utilizes equimolar concentrations of sodium and glucose to maximize sodium uptake in the small intestine. Rapid diagnostic tests, such as stool dipsticks or darkfield microscopy, can also be used in settings where stool culture is not readily available.
- An estimated 1.3 to 4 million individuals around the globe get cholera each year, and 21,000 to 143,000 people compromise their lives.
Thelansis’s “Cholera Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Cholera
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights of Cholera across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cholera Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment